Active

Contract Opportunity

Illumina Next Seq 500/550 High Output Kits

• Product Service Code: 6550-In Vitro Diagnostic Substances, Reagents, Test Kits and Sets


• NAICS Code: 325413-In Vitro Diagnostic Substance Manufacturing (Small Business Size Standards, $1,250 Average Annual Receipts)


• Place of Performance: Bethesda, MD 20892

POTS: 24-006354

Description:

This is a notice of intent, not a request for a quotation. A solicitation document will not be issued, and quotations will not be requested.

The National Institutes of Health (NIH), Office of Purchasing and Contracts on behalf of the Center for Cellular Engineering intends to award a fixed price contract to Illumina, Inc. located at 5200 Illumina Way in San Diego, CA 921122 on a sole source basis to provide Illumina reagent kits.

Catalog No.: 20024908 Description: NextSeq 500/550 High Output Kit v2.5 (300 Cycles)

Illumina, Inc. is the sole manufacturer of the NextSeq 500/550 v2.5 sequencing reagent kits used in CAR-T cells manufacturing and the only reagents compatible with the bench top Illumina NextSeq 550 Sequencer system. Other manufacturer reagents are not compatible with the Illumina NextSeq 550 Sequencer system. If other manufacturer reagents are used, it could damage the instrument and result in inaccurate in the CAR-T cells manufacturing workflow process that ultimately could cause harm to the patient.

The Center for Cellular Engineering (CCE) is responsible for the manufacture of human cells and tissue-based products utilized in phase I/II clinical protocols for transplantation, adoptive immunotherapy and gene therapy conducted in the Clinical Center at the NIH. Cell processing procedures are tailored to each of the 30 or more different patient-care clinical research protocols supported, including CAR-T cells and iPSCs. Also, regarding Institute research support it: 1)Develops biologics collection and manufacturing processes to support clinical trials, 2) Collects, manufactures and distribute blood components for in vitro research use, 3) Collaboration in the design, planning, execution and data analysis of clinical studies, 4) Collects and manufactures specialized cellular products to support clinical trials and, 5) Develops and evaluate assays for clinical application and biologics safety testing and cellular characterization.

This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements.

Interested parties may identify their interest and capabilities in response to this posting. The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government.

Comments to this announcement, referencing this posting number in the email subject line, may be submitted to the Office of Purchasing and Contracts, prior to the closing date specified in this announcement, electronically to the attention of Sheri Eiri, Contract Specialist, sheri.eiri.nih.gov by the due date April 5, 2024, and time marked in this notice.

Attachments/Links